Bath & Body Works
BBWI
$21.07
+8.27%
Bath & Body Works, Inc. is a leading specialty retailer in the Consumer Cyclical sector, operating under its namesake brand along with C.O. Bigelow and White Barn, primarily focused on home fragrance and fragrant body care products. The company is a dominant market leader in its niche, distinguished by its extensive brick-and-mortar footprint of over 1,900 stores in North America and a powerful brand identity built on seasonal offerings and a direct-to-consumer model. The current investor narrative centers on navigating a challenging post-pandemic normalization of consumer spending patterns, with recent financials showing a year-over-year revenue decline, while the market debates the company's ability to reignite growth through international expansion, digital channel development, and category adjacencies like men's and lip products amidst a volatile retail environment.…
BBWI
Bath & Body Works
$21.07
BBWI 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bath & Body Works's 12-month outlook, with a consensus price target around $27.39 and implied upside of +30.0% versus the current price.
Average Target
$27.39
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$17 - $27
Analyst target range
Analyst coverage for BBWI is limited, with only 5 analysts providing estimates, indicating it is a mid-cap stock with less institutional scrutiny which can lead to higher volatility. The consensus sentiment appears neutral, as evidenced by recent institutional ratings from firms like Barclays and Telsey Advisory Group maintaining 'Equal Weight' and 'Market Perform' stances, and a notable downgrade from Citigroup from 'Buy' to 'Neutral' in February 2026. The average EPS estimate for the forward period is $3.15, with a range from $2.87 to $3.42, implying a forward P/E of approximately 6.2x at the current price, but a specific consensus price target and implied upside are not available in the provided data. The wide EPS estimate range (a $0.55 spread) signals meaningful uncertainty among the covering analysts regarding the company's earnings power, likely tied to debates over consumer spending resilience and margin trajectory; the high estimate likely assumes successful execution on growth initiatives, while the low estimate may price in further sales erosion or margin compression.
Bulls vs Bears: BBWI Investment Factors
The evidence currently tilts bearish, primarily due to the deteriorating fundamental picture of declining revenue and compressing margins, coupled with severe technical underperformance. The bull case rests almost entirely on a deeply discounted valuation and strong cash flow, betting on a stabilization that has not yet materialized. The single most important tension in the investment debate is whether BBWI's dominant brand and cash-generative model can overcome post-pandemic normalization and reignite growth, or if the current revenue decline marks the beginning of a longer-term secular challenge for the brick-and-mortar-focused retailer. The resolution of this growth question will determine if the stock is a value trap or a value opportunity.
Bullish
- Deeply discounted valuation: The stock trades at a trailing P/E of 7.11x and a forward P/E of 6.77x, which is near the bottom of its historical range and represents a significant contraction from prior highs. This multiple is low for a profitable, cash-generative retailer, suggesting the market has priced in substantial pessimism, creating a potential value opportunity if fundamentals stabilize.
- Strong free cash flow generation: The company generated $865 million in TTM free cash flow, providing ample liquidity to fund its 3.6% dividend yield and share repurchases without external financing. This robust cash generation, supported by a 45.7% gross margin, underpins financial resilience despite a leveraged balance sheet.
- Dominant market position and brand: As a leading specialty retailer with over 1,900 stores in North America, BBWI holds a dominant position in home fragrance and body care. Its powerful brand identity and direct-to-consumer model provide a solid foundation for future growth initiatives in international and digital channels.
- Significant technical support near current price: The stock is trading 43% above its 52-week low of $14.28, which provides a clear and tested level of major support. The recent 3.5% one-month price gain, while modest, indicates potential stabilization after a severe 56% maximum drawdown.
Bearish
- Revenue contraction and growth stall: Q4 FY25 revenue declined 2.26% YoY to $2.724B, continuing a trend of deceleration from the prior year's $2.787B. This top-line pressure reflects a challenging post-pandemic normalization of consumer spending on discretionary categories, raising questions about the company's ability to reignite growth.
- Margin compression and profitability pressure: The Q4 operating margin compressed to 21.99% from 24.33% a year ago, signaling rising cost pressures or increased promotional activity. While net margins remain healthy at 14.79%, this erosion, if sustained, threatens the company's earnings power and cash flow generation.
- Severe underperformance and high volatility: The stock has declined 25.7% over the past year, underperforming the S&P 500 by approximately 48.6 percentage points. With a beta of 1.387, the stock is 39% more volatile than the market, amplifying downside risk during sector-wide sell-offs or economic weakness.
- Negative shareholder equity and analyst uncertainty: The balance sheet shows a negative debt-to-equity ratio of -3.87, indicating negative shareholder equity, which can be a concern for traditional value investors. Furthermore, analyst coverage is limited (5 analysts) with a wide EPS estimate range ($2.87-$3.42), reflecting significant uncertainty over the company's earnings trajectory.
BBWI Technical Analysis
The stock is entrenched in a pronounced downtrend, having declined 25.70% over the past year, significantly underperforming the S&P 500, which gained 22.86% over the same period. With a current price of $19.40, BBWI is trading approximately 43% above its 52-week low of $14.28 but a substantial 43% below its 52-week high of $33.96, positioning it in the lower-middle of its annual range and suggesting it is in a phase of deep consolidation after a severe sell-off. Recent short-term momentum shows modest signs of stabilization, with the stock up 3.52% over the past month, though this follows a sharp 56.36% maximum drawdown, indicating extreme volatility and a lack of sustained bullish conviction. The 3-month price change remains negative at -0.51%, highlighting that the recent minor uptick has not yet reversed the medium-term bearish trend, and the stock's high beta of 1.387 confirms it is approximately 39% more volatile than the broader market, amplifying both risk and potential reward. Key technical levels are clearly defined, with immediate resistance near the $24-$25 area (the February highs) and critical support at the 52-week low of $14.28; a decisive break below this support could trigger another leg down, while a sustained move above the $24 resistance would be necessary to signal a potential trend reversal, though the high beta necessitates careful risk management for any position.
Beta
1.39
1.39x market volatility
Max Drawdown
-56.4%
Largest decline past year
52-Week Range
$14-$34
Price range past year
Annual Return
-18.4%
Cumulative gain past year
| Period | BBWI Return | S&P 500 |
|---|---|---|
| 1m | +23.3% | +1.5% |
| 3m | +5.5% | +13.4% |
| 6m | +7.4% | +10.9% |
| 1y | -18.4% | +24.5% |
| ytd | +1.6% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BBWI Fundamental Analysis
Revenue growth has turned negative, with the most recent quarterly (Q4 FY25) revenue of $2.724 billion reflecting a 2.26% year-over-year decline, continuing a trend of deceleration from the prior year's Q4 revenue of $2.787 billion. The company's two main segments, Bath & Body Works ($1.704B) and Victoria's Secret ($1.614B), contributed nearly equally in the latest period, but the overall top-line contraction signals pressure on the core business amidst a normalized post-pandemic demand environment. Profitability remains intact but is under pressure, with Q4 net income of $403 million and a net margin of 14.79%, supported by a robust gross margin of 45.67%; however, operating margins have compressed year-over-year, with the Q4 operating margin at 21.99% compared to 24.33% in the prior-year quarter, indicating rising cost pressures or promotional activity. The balance sheet shows a leveraged but cash-generative profile, with a negative debt-to-equity ratio of -3.87 (indicating negative shareholder equity) and a current ratio of 1.27, but the company generated substantial free cash flow of $865 million over the trailing twelve months, providing liquidity to fund operations, dividends, and share repurchases without immediate external financing needs.
Quarterly Revenue
$2.7B
2026-01
Revenue YoY Growth
-0.02%
YoY Comparison
Gross Margin
+0.45%
Latest Quarter
Free Cash Flow
$865000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BBWI Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is 7.11x, while the forward P/E is notably lower at 6.77x, indicating the market expects modest earnings growth or a stabilization in profitability. Compared to the provided industry averages, BBWI's trailing P/E of 7.11x and Price-to-Sales (P/S) ratio of 0.63x appear deeply discounted relative to specialty retail peers, though direct industry average multiples are not provided in the data for a quantified spread. Historically, the stock's own valuation has contracted dramatically; its current trailing P/E of 7.11x is near the bottom of its observable historical range from the provided data (which has seen P/E ratios as high as 51.62x in late 2021), suggesting the market has priced in significant pessimism regarding future growth and profitability, potentially offering a value opportunity if fundamentals stabilize.
PE
7.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~52x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BBWI faces clear financial headwinds, including a 2.26% year-over-year revenue decline in its latest quarter and operating margin compression from 24.33% to 21.99%. While the company generates substantial free cash flow ($865M TTM), its balance sheet is leveraged, with negative shareholder equity (Debt/Equity of -3.87), indicating that asset values on the books are below debt levels. This financial structure, combined with a high dependence on North American brick-and-mortar sales (77% of revenue), creates vulnerability if consumer discretionary spending weakens further, potentially accelerating the earnings decline already reflected in the wide analyst EPS estimate range.
Market & Competitive Risks: The stock's high beta of 1.387 makes it significantly more volatile than the market, exposing investors to amplified downside during broader market corrections or sector rotations away from consumer cyclicals. Valuation compression risk is a double-edged sword; while the current P/E of ~7x appears cheap, it could compress further if growth remains elusive, especially given the stock's history of trading at much higher multiples. Competitive and macro risks are heightened, as the company's niche in home fragrance and body care is susceptible to shifts in consumer preferences, private label competition, and economic sensitivity, with recent analyst downgrades (e.g., Citigroup to Neutral) signaling waning confidence in a near-term recovery.
Worst-Case Scenario: The most damaging scenario involves a recessionary downturn in consumer spending, leading to a further acceleration in revenue declines and severe margin pressure from increased promotions. This could trigger a breach of the key $14.28 support level (the 52-week low), leading to a downward spiral as stop-losses are triggered and negative sentiment feeds on itself. Given the stock's high volatility, a realistic downside from the current price of $19.40 could approach -35% to the 52-week low, representing a loss of nearly $7 per share. A sustained break below $14 could see the stock test levels not seen in years, as the negative equity on the balance sheet becomes a more prominent concern for investors.